Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 4, 2014, Pages

  Londoño, Ana C ^a   Mora, Carlos A ^b  

^a Neurologic Institute of Colombia   (Colombia)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM;

DISABILITY; EXCITOTOXICITY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; INDIVIDUALIZATION; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 85010003697     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000045     Document Type: Review

References (36)

1. Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr Opin Neurol 2012;25(SUPPL. 1):S4-S10.
2. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 2012;25(SUPPL. 1):S11-S19.
3. Tornatore C, Phillips JT, Khan O, Miller AE, Barnes CJ. Practice patterns of US neurologists in patients with CIS, RRMS, or RIS. Neurol Clin Pract 2012;2:48-57.
4. Montalban X, Tintore M, Swanton F, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-434.
5. Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014;13:518-524.
6. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol Epub 2013 Dec 14. doi:10.1016/j.expneurol.2013.12.003.
7. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014;62:1816-1830. doi:10.1002/glia.22597.
8. Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia 2013;61:453-465.
9. Yamasaki R, Lu H, Butovsky O, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 2014;211:1533-1549. doi:10.1084/jem20132477.
10. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27: 119-145. doi:10.1146/annurev.immunol.021908.132528.
11. Lisak RP, Benjamins JA, Nedelkoska L, et al. Secretory products of multiple sclerosis B-cells are cytotoxic to oli-godendroglia in vitro. J Neuroimmunol 2012;246:85-95.
12. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688.
13. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia 2013;61:1939-1958.
14. Lundgaard I, Osorio MJ, Kress BT, Sanggaard S, Nedergaard M. White matter astrocytes in health and disease. Neuroscience 2014;276:161-173. doi:10.1016/j.neuroscience.2013.10.050.
15. Nathoo N, Yong VW, Dunn JF. Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models. Neuroimage Clin 2014; 4:743-756. doi:10.1016/j.nicl.2014.04.011.
16. Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larssor HB. Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 2013;4:182-189.
17. Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006;65:855-865.
18. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-174.
19. Takata F, Dohgu S, Matsumoto J, et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-a, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflammation 2011;8:106. doi:10.1186/1742-2094-8-106.
20. + T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J Immunol 2012; 189:5057-5065.
21. Olmos G, Lladó J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm 2014;2014:861231. doi:10.1155/2014/861231.
22. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537-544.
23. Langkammer C, Scheurer F, Krebs N, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012; 62:1593-1599.
24. Sbardella E, Tona F, Petsas N, Pantano P. DTI measurements in multiple sclerosis: evaluation of brain damage and clinical implications. Mult Scler Int 2013;2013: 671730. doi:10.1155/2013/671730.
25. Qian W, Chan Q, Mak H, et al. Quantitative assessment of the cervical spinal cord damage in neuromyelitis optica using diffusion tensor imaging at 3 Tesla. J Magn Reson Imaging 2011;33:1312-1320.
26. Yu CS, Lin FC, Li KC, et al. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 2006;27:1009-1015.
27. Ciccarelli O, Barkhof F, Bodini B, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol 2014;13:807-822.
28. Bertholdo D, Watcharakorn A, Castillo M. Brain proton magnetic resonance spectroscopy: introduction and overview. Neuroimaging Clin N Am 2013;23:359-380.
29. Stromillo ML, Giorgio A, Rossi F, et al. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology 2013;80:2090-2094.
30. Rovira A, Alonso J. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am 2013;23:459-474.
31. Llufriu S, Kornak J, Ratiney H, et al. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol 2014;71:840-847. doi:10.1001/jamaneuro.2014.895.
32. Azevedo CJ, Kornak J, Chu P, et al. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol 2014; 76:269-278. doi:10.1002/ana.24202.
33. Choi IY, Lee SP, Denney DR, Lynch SG. Lower levels of glutathione (GSH) in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 2011;17:289-296.
34. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol 2014;13:113-126.
35. 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers. Alzheimers Dement 2014;10: 552-561. doi:10.1016/j.jalz.2013.08.282.29.
36. Daams M, Geurts JJ, Barkhof F. Cortical imaging in multiple sclerosis: recent findings and "grand challenges". Curr Opin Neurol 2013;26:345-352. doi:10.1097/WCO.0b013e328362a864.